Baseline corticosteroid use and discontinuation of bevacizumab-containing therapy independent adverse prognostic factors. »
02/14/26

4HB does not modify growth or activity of malignant or non-malignant breast cells. »
02/14/26

Calibration and DCA indicated good agreement between predicted and observed outcomes. »
02/14/26

IKBKE facilitates aggressive phenotype of PDAC cells. »
02/16/26

Only patients in high-risk group benefited from postoperative chemoradiotherapy. »
02/17/26

Novel histone reader CBFA2T2 recognizes non-mutated or un-modified histone H3K27. »
02/17/26

Cone-beam-CT-guided oART feasible in routine prostate cancer practice. »
02/19/26

Association between diagnosis-to-treatment intervals beyond about one month and worse survival. »
02/19/26

Comprehensive CIPN assessment during and after chemotherapy feasible. »
02/19/26

ERK1/2 signaling pathway activated in A549 and H1299 cells. »
02/19/26